Skip to main navigation Skip to search Skip to main content

Pilot study on the feasibility of PET/CT lymphoscintigraphy with Zr-89-nanocolloidal albumin for sentinel node identification in oral cancer patients

  • D.A. Heuveling
  • , A. van Schie
  • , D.J. Vugts
  • , N.H. Hendrikse
  • , M. Yaqub
  • , O.S. Hoekstra
  • , K.H. Karagozoglu
  • , C.R. Leemans
  • , G.A.M.S. van Dongen
  • , R. de Bree

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

With conventional imaging techniques such as planar lymphoscintigraphy and SPECT/CT, preoperative sentinel node (SN) identification can be difficult when the SN is near the primary tumor, as is the case in floor-of-mouth carcinomas. PET/CT lymphoscintigraphy may improve the detection and localization of such SNs. Methods: In this study, the clinical feasibility of PET/CT lymphoscintigraphy using 89Zr-nanocolloidal albumin was evaluated in 5 oral cancer patients. PET/CT lymphoscintigraphy was performed after peritumoral injection of 89Zr-nanocolloidal albumin. The routine SN procedure, including SPECT/CT using 99mTc-nanocolloidal albumin, was performed on the same patients 7-9 d after the injection of 89Zr-nanocolloidal albumin. Results: Comparison of radiocolloid distribution on PET/CT and SPECT/CT showed identical drainage patterns. Moreover, PET/CT was able to identify additional foci near the primary tumor. Conclusion: This pilot PET/CT study on SN detection indicated that lymphoscintigraphy using 89Zr-nanocolloidal albumin is feasible.
Original languageEnglish
Pages (from-to)585-589
JournalJNM : The Journal of Nuclear Medicine
Volume54
Issue number4
DOIs
Publication statusPublished - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Pilot study on the feasibility of PET/CT lymphoscintigraphy with Zr-89-nanocolloidal albumin for sentinel node identification in oral cancer patients'. Together they form a unique fingerprint.

Cite this